Onychomycosis has several clinical presentations and is caused by various infectious organisms.
Objective
To provide guidance for selection of appropriate treatment.
Methods
The literature on onychomycosis management was reviewed to generate an evidence-based decision tree.
Results and Conclusion
Several options are available: terbinafine, itraconazole, fluconazole, ciclopirox 8% nail lacquer, efinaconazole 10% nail solution, and laser therapy. Further studies on lasers are needed before use can be recommended. Nondermatophyte molds or mixed infection can be managed with terbinafine or itraconazole with or without topicals. Itraconazole, fluconazole, and efinaconazole can be used for Candida infection. For dermatophytes, topicals can be considered for mild to moderate onychomycosis. For moderate to severe cases, any oral monotherapy can be used; however, we suggest terbinafine if there is a possibility of a drug interaction. These recommendations can be applied for all ages, immune function, or metabolic status, but proper monitoring and contraindications should be taken into consideration.
Get full access to this article
View all access options for this article.
References
1.
GuptaAK, JainHC, LyndeCW.Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients.J Am Acad Dermatol2000; 43: 244–8, doi:10.1067/mjd.2000.104794.
2.
GuptaAK, PoulinY, LyndeCW.Canadian perspectives on antifungal treatment for onychomycosis.J Cutan Med Surg2006; 10 Suppl 2: S34–8.
GuptaAK, SimpsonFC.Laser therapy for onychomycosis.J Cutan Med Surg2013; 17: 301–7.
8.
ElewskiBE, RichP, PollakR.Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies.J Am Acad Dermatol2013; 68: 600–8, doi:10.1016/j.jaad.2012.10.013.
9.
DuhardE, CoudiereP, VoisardJ-J.[Management of presumed onychomycosis in private practice].Ann Dermatol Vénéréol2006; 133: 11–5, doi:10.1016/S0151-9638(06)70835-3.
10.
GuibalF, BaranR, DuhardE.[Epidemiology and management of onychomycosis in private dermatological practice in France].Ann Dermatol Vénéréol2008; 135: 561–6, doi:10.1016/j.annder.2008.05.004.
11.
Vander StratenMR, BalkisMM, GhannoumMA.The role of nondermatophyte molds in onychomycosis: diagnosis and treatment.Dermatol Ther2002; 15: 89–98, doi:10.1046/j.1529-8019.2002.01522.x.
GuptaA, NakriekoK-A.Molecular determination of mixed infections of dermatophytes and nondermatophyte moulds in individuals with onychomycosis.J Am Podiatr Med Assoc2014. [In press]
14.
GuptaAK, KohliY.In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.Br J Dermatol2003; 149: 296–305, doi:10.1046/j.1365-2133.2003.05418.x.
15.
BarrosME, HamdanJS.Determination of susceptibility/resistance to antifungal drugs of Trichophyton mentagrophytes isolates by a macrodilution method.Can J Microbiol2005; 51: 983–7, doi:10.1139/w05-100.
16.
GuptaAK.In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.Med Mycol2005; 43: 179–85, doi:10.1080/13693780410001731583.
ZalacainA, ObradorC, MartinezJP.Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain.Med Mycol Off Publ Int Soc Hum Anim Mycol2011; 49: 495–9.
19.
SilvaLB, de OliveiraDBC, da SilvaBV.Identification and antifungal susceptibility of fungi isolated from dermatomycoses.J Eur Acad Dermatol Venereol2013, doi:10.1111/jdv.12151 [Epub ahead of print]
20.
Jo SiuWJ, TatsumiY, SendaH.Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.Antimicrob Agents Chemother2013; 57: 1610–6, doi:10.1128/AAC.02056-12.
21.
Torres-RodríguezJM, Madrenys-BrunetN, SiddatM.Aspergillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs.J Eur Acad Dermatol Venereol1998; 11: 25–31, doi:10.1111/j.1468-3083.1998.tb00949.x.
22.
GuilhermettiE, TakahachiG, ShinobuCS.Fusarium spp. as agents of onychomycosis in immunocompetent hosts.Int J Dermatol2007; 46: 822–6, doi:10.1111/j.1365-4632.2007.03120.x.
23.
FigueiredoVT, de Assis SantosD, ResendeMA.Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.Mycopathologia2007; 164: 27–33, doi:10.1007/s11046-007-9027-6.
24.
HeesH, RaulinC, BaumlerW.Laser treatment of onychomycosis: an in vitro pilot study.J Dtsch Dermatol Ges2012; 10: 913–8.
25.
VuralE, WinfieldHL, ShingletonAW.The effects of laser irradiation on Trichophyton rubrum growth.Lasers Med Sci2008; 23: 349–53, doi:10.1007/s10103-007-0492-4.
26.
ChoiMJ, ZhengZ, GooB.Antifungal effects of a 1,444-nm neodymium:yttrium-aluminium-garnet laser on onychomycosis: a pilot study.J Dermatolog Treat2014; 25: 294–7, doi:10.3109/09546634.2012.714455.
27.
ManevitchZ, LevD, HochbergM.Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis.Photochem Photobiol2010; 86: 476–9, doi:10.1111/j.1751-1097.2009.00672.x.
28.
BornsteinE, HermansW, GridleyS.Near-infrared photo-inactivation of bacteria and fungi at physiologic temperatures.Photochem Photobiol2009; 85: 1364–74, doi:10.1111/j.1751-1097.2009.00615.x.
29.
GuptaAK, RyderJE, JohnsonAM.Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.Br J Dermatol2004; 150: 537–4, doi:10.1046/j.1365-2133.2003.05728.x.
30.
TrivediNA, ShahPC.A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis.Indian J Dermatol2010; 55: 198–9, doi:10.4103/0019-5154.62746.
31.
GuptaAK, FleckmanP, BaranR.Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.J Am Acad Dermatol2000; 43 (4 Suppl): S70–80, doi:10.1067/mjd.2000.109071.
32.
AvnerS, NirN, HenriT.Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.J Dermatolog Treat2005; 16: 327–30, doi:10.1080/09546630500420183.
33.
GuptaAK.Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.J Drugs Dermatol2005; 4: 481–5.
34.
JaiswalA, SharmaRP, GargAP.An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.Indian J Dermatol Venereol Leprol2007; 73: 393–6, doi:10.4103/0378-6323.37056.
35.
TschenEH, BuckoAD, OizumiN.Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.J Drugs Dermatol2013; 12: 186–92.
36.
GuptaAK, Drummond-MainC, CooperEA.Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment.J Am Acad Dermatol2012; 66: 494–502, doi:10.1016/j.jaad.2011.02.038.
37.
GuptaAK, PaquetM, SimpsonFC.Therapies for the treatment of onychomycosis.Clin Dermatol2013; 31: 544–54, doi:10.1016/j.clindermatol.2013.06.011.
38.
GuptaAK, Gregurek-NovakT.Efficacy of itraconazole, terbina-fine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.Dermatol Basel Switz2001; 202: 235–8, doi:10.1159/000051643.
39.
UlbrichtH, WörzK.[Therapy with ciclopirox lacquer of onychomycoses caused by molds].Mycoses1994; 37: 97–100.
40.
DourmishevL, BardarovE, DourmishevA.Fluconazole in the treatment of onychomycosis.Acta Med Bulg2006; 33: 60–9.
41.
LebwohlMG, DanielCR, LeydenJ.Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis.Int J Dermatol2001; 40: 358–60, doi:10.1046/j.1365-4362.2001.01204.x.
42.
WarshawEM, NelsonD, CarverSM.A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis.Int J Dermatol2005; 44: 785–8, doi:10.1111/j.1365-4632.2004.02117.x.
43.
NoltingS, BrautigamM, WeidingerG.Terbinafine in onychomycosis with involvement by non-dermatophytic fungi.Br J Dermatol1994; 130: 16–21, doi:10.1111/j.1365-2133.1994.tb06088.x.
44.
GuptaAK, De DonckerP, HanekeE.Itraconazole pulse therapy for the treatment of Candida onychomycosis.J Eur Acad Dermatol Venereol2001; 15: 112–5, doi:10.1046/j.1468-3083.2001.00206.x.
45.
FialloP, CardoPP.Age as limiting factor of the efficacy of itraconazole for treatment of onychomycosis.Mycoses2001; 44: 191–4, doi:10.1046/j.1439-0507.2001.00645.x.
46.
RigopoulosD, KatoulisAC, IoannidesD.A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis.Br J Dermatol2003; 149: 151–6, doi:10.1046/j.1365-2133.2003.05381.x.
47.
CarneyC, CantrellW, WarnerJ.Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser.J Am Acad Dermatol2013; 69: 578–82, doi:10.1016/j.jaad.2013.04.054.
48.
LandsmanAS, RobbinsAH, AngeliniPF.Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure.J Am Podiatr Med Assoc2010; 100: 166–77, doi:10.7547/1000166.
49.
HayRJ, BaranR.Onychomycosis: a proposed revision of the clinical classification.J Am Acad Dermatol2011; 65: 1219–27, doi:10.1016/j.jaad.2010.09.730.
50.
VenderRB, LyndeCW, PoulinY.Prevalence and epidemiology of onychomycosis.J Cutan Med Surg2006; 10 Suppl 2: S28–33.
51.
VeerP, PatwardhanNS, DamleAS.Study of onychomycosis: prevailing fungi and pattern of infection.Indian J Med Microbiol2007; 25: 53–6, doi:10.4103/0255-0857.31063.
52.
RongiolettiF, PersiA, TripodiS.Proximal white subungual onychomycosis: a sign of immunodeficiency.J Am Acad Dermatol1994; 30: 129–30, doi:10.1016/S0190-9622(08)81900-7.
53.
WeinbergJM, KoestenblattEK, DonPC.Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature.Acta Derm Venereol1999; 79: 81–2, doi:10.1080/000155599750011796.
54.
ArcaE, TaştanHB, AkarA.An open, randomized, comparative study of oral fluconazole, itraconazole and terbina-fine therapy in onychomycosis.J Dermatolog Treat2002; 13: 3–9, doi:10.1080/09546630252775171.
55.
DrakeLA, ShearNH, ArletteJP.Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial.J Am Acad Dermatol1997; 37: 740–5, doi:10.1016/S0190-9622(97)70111-7.
56.
GoodfieldMJ.Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.Br J Dermatol1992; 126: 33–5, doi:10.1111/j.1365-2133.1992.tb00007.x.
57.
KejdaJ.Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis.Postgrad Med1999; Spec No: 12-15.
58.
AmanS, AkbarTM, HussainI.Itraconazole pulse therapy in the treatment of disto-lateral subungual onychomycosis.J Coll Physicians Surg Pak2003; 13: 618–20.
59.
HavuV, BrandtH, HeikkiläH.A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis.Br J Dermatol1997; 136: 230–4, doi:10.1111/j.1365-2133.1997.tb14902.x.
60.
LingMR, SwinyerLJ, JarrattMT.Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.J Am Acad Dermatol1998; 38 (6 Pt 2): S95–102, doi:10.1016/S0190-9622(98)70492-X.
61.
ScherRK, BrenemanD, RichP.Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.J Am Acad Dermatol1998; 38 (6 Pt 2): S77–86, doi:10.1016/S0190-9622(98)70490-6.
62.
GuptaAK, JosephWS.Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.J Am Podiatr Med Assoc2000; 90: 495–501, doi:10.7547/87507315-90-10-495.
63.
SchalkaS, NunesS, Gomes NetoA.Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.An Bras Dermatol2012; 87: 19–25.
64.
LeeKJ, LeeYB, LeeJY.Proximal subungual onychomycosis in a patient with classic Kaposi sarcoma caused by Trichophyton rubrum.Ann Dermatol2011; 23 Suppl 1: S11–5, doi:10.5021/ad.2011.23.S1.S11.
65.
Tlacuilo-ParraA, Guevara-GutiérrezE, MayorgaJ.Proximal white subungual onychomycosis caused by Microsporum canis in systemic lupus erythematosus.Rheumatol Int2002; 21: 250–2, doi:10.1007/s00296-002-0178-y.
66.
BaranR.Proximal subungual Candida onychomycosis. An unusual manifestation of chronic mucocutaneous candidosis.Br J Dermatol1997; 137: 286–8, doi:10.1046/j. 1365-2133.1997.18221900.x.
67.
AmanS, NadeemM, HaroonTS.Successful treatment of proximal white subungual onychomycosis with oral terbinafine therapy.J Coll Physicians Surg Pak2008; 18: 728–9.
68.
TostiA, PiracciniBM.Proximal subungual onychomycosis due to Aspergillus niger. report of two cases.Br J Dermatol1998; 139: 156–7, doi:10.1046/j.1365-2133.1998.02340.x.
69.
PiracciniBM, MorelliR, StinchiC.Proximal subungual onychomycosis due to Microsporum canis.Br J Dermatol1996; 134: 175–7, doi:10.1111/j.1365-2133.1996.tb07863.x.
70.
BaranR, TostiA, PiracciniBM.Uncommon clinical patterns of Fusarium nail infection: report of three cases.Br J Dermatol1997; 136: 424–7, doi:10.1111/j.1365-2133.1997.tb14959.x.
71.
GianniC, CerriA, CrostiC.Unusual clinical features of fingernail infection by Fusarium oxysporum.Mycoses1997; 40: 455–9, doi:10.1111/j.1439-0507.1997.tb00184.x.
72.
LlovoJ, PrietoE, VazquezH.Onychomycosis due to Onychocola canadensis: report of the first two Spanish cases.Med Mycol2002; 40: 209–12, doi:10.1080/mmy.40.2.209.212.
73.
TostiA, PiracciniBM, StinchiC.Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.Br J Dermatol1996; 135: 799–802, doi:10.1111/j.1365-2133.1996.tb03895.x.
74.
SigurgeirssonB.Prognostic factors for cure following treatment of onychomycosis.J Eur Acad Dermatol Venereol2010; 24: 679–84, doi:10.1111/j.1468-3083.2009.03487.x.
75.
LechaM, EffendyI, Feuilhade de ChauvinM.Treatment options - development of consensus guidelines.J Eur Acad Dermatol Venereol2005; 19: 25–33, doi:10.1111/j.1468-3083.2005.01284.x.
76.
SergeevAY, GuptaAK, SergeevYV.The scoring clinical index for onychomycosis (SCIO index).Skin Ther Lett2002; 7: 6–7.
77.
WarshawEM, TraywickCA, HoffmanAA.Naildex: pilot evaluation of an onychodystrophy severity instrument.Mycoses2008; 51: 14–20.
78.
BaranR, HayRJ, GardunoJI.Review of antifungal therapy and the severity index for assessing onychomycosis: part I.J Dermatolog Treat2008; 19: 72–81, doi:10.1080/09546630701243418.
79.
CarneyC, TostiA, DanielR.A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index.Arch Dermatol2011; 147: 1277–82, doi:10.1001/archdermatol.2011.267.
80.
ZhangR, WangD, ZhuoF.Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis.Chin Med J (Engl)2012; 125: 3288–91.
SinghG, HaneefNS, UdayA.Nail changes and disorders among the elderly.Indian J Dermatol Venereol Leprol2005; 71: 386–92, doi:10.4103/0378-6323.18941.
83.
BaranR.The nail in the elderly.Clin Dermatol2011; 29: 54–60, doi:10.1016/j.clindermatol.2010.07.008.
84.
DewanSK, ZhengS, XiaS.Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections.Chin Med J (Engl)2012; 125: 3325–31.
85.
ChiouCC, WalshTJ, GrollAH.Clinical pharmacology of antifungal agents in pediatric patients.Expert Opin Pharmacother2007; 8: 2465–89, doi:10.1517/14656566.8.15.2465.
86.
EndoJO, WongJW, NormanRA.Geriatric dermatology: part I. Geriatric pharmacology for the dermatologist.J Am Acad Dermatol2013; 68: 521.e1-10, doi:10.1016/j.jaad.2012.10.063.
87.
GuptaAK, PaquetM.Systemic antifungals to treat onychomycosis in children: a systematic review.Pediatr Dermatol2013; 30: 294–302, doi:10.1111/pde.12048.
88.
GuptaAK, SkinnerAR.Onychomycosis in children: a brief overview with treatment strategies.Pediatr Dermatol2004; 21: 74–9, doi:10.1111/j.0736-8046.2004.21117.x.
89.
FriedlanderSF, ChanYC, ChanYH.Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.Pediatr Dermatol2013; 30: 316–22, doi:10.1111/pde.12064.
90.
MalayDS, YiS, BorowskyP.Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial.J Foot Ankle Surg2009; 48: 294–308, doi:10.1053/j.jfas.2008.12.012.
91.
TavakkolA, FellmanS, KianifardF.Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.Am J Geriatr Pharmacother2006; 4: 1–13, doi:10.1016/j.amjopharm.2005.12.012.
92.
SmithEB, SteinLF, FivensonDP.The safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet.Int J Dermatol2000; 39: 861–4, doi:10.1046/j.1365-4362.2000.00087-2.x.
93.
GuptaAK, KonnikovN, LyndeCW.Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.J Am Acad Dermatol2001; 44: 479–84, doi:10.1067/mjd.2001.110874.
94.
PollakR, BillsteinSA.Safety of oral terbinafine for toenail onychomycosis.J Am Podiatr Med Assoc1997; 87: 565–70, doi:10.7547/87507315-87-12-565.
95.
HallM, MonkaC, KruppP.Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.Arch Dermatol1997; 133: 1213–9, doi:10.1001/archderm.1997.03890460029004.
96.
SadighhaA, MohagheghzahedG.Onychomycosis: report on eXperience with itraconazole in 37 patients aged older than 50 years: a multivariate regression.Clin EXp Dermatol2009; 34: 924–5, doi:10.1111/j.1365-2230.2008.03174.x.
97.
VickersAE, SinclairJR, ZollingerM.Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.Drug Metab Dispos Biol Fate Chem1999; 27: 1029–38.
JensenJC.Pharmacokinetics of Lamisil in humans.J Dermatolog Treat1990; 1: 15–8, doi:10.3109/09546639009089024.
100.
GuptaAK.Systemic antifungals agents. In: WolvertonS, editor. Comprehensive dermatologic drug therapy.3rd ed. Philadelphia: WB Saunders;2012. p. 98–120.
101.
DebruyneD, CoquerelA.Pharmacokinetics of antifungal agents in onychomycoses.Clin Pharmacokinet2001; 40: 441–72, doi:10.2165/00003088-200140060-00005.
102.
LestnerJ, HopeWW.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.Expert Opin Drug Metab Toxicol2013; 9: 911–26, doi:10.1517/17425255.2013.794785.
SagirA, SchmittM, DilgerK.Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.Digestion2003; 68: 41–8, doi:10.1159/000073224.
ElewskiB, TavakkolA.Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.Ther Clin Risk Manag2005; 1: 299–306.
107.
ParedesAH, LewisJH.Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection.Ann Pharmacother2007; 41: 880–4, doi:10.1345/aph.1H400.
108.
MayserP, FreundV, BudihardjaD.Toenail onychomycosis in diabetic patients: issues and management.Am J Clin Dermatol2009; 10: 211–20, doi:10.2165/00128071-200910040-00001.
109.
RichP.Special patient populations: onychomycosis in the diabetic patient.J Am Acad Dermatol1996; 35 (3 Pt 2): S10–2, doi:10.1016/S0190-9622(96)90063-8.
110.
SeebacherC, NietschKH, UlbrichtHM.A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.Cutis Cutan Med Pract2001; 68: 17–22.
111.
BrennerMA, HarklessLB, MendicinoRW.Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes.J Am Podiatr Med Assoc2007; 97: 195–202, doi:10.7547/0970195.
112.
SumikawaM, EgawaT, HondaI.Effects of foot care intervention including nail drilling combined with topical anti-fungal application in diabetic patients with onychomycosis.J Dermatol2007; 34: 456–64, doi:10.1111/j.1346-8138.2007.00310.x.
113.
BarberK, ClaveauJ, ThomasR.Review of treatment for onychomycosis: consideration for special populations.J Cutan Med Surg2006; 10 Suppl 2: S48–53.
114.
BohannonNJ, StrejaL.Effectiveness of terbinafine therapy for toenail onychomycosis in persons with diabetes.Diabetes2000; 49: A195, doi:10.2337/diabetes.49.2.195.
115.
GuptaAK, GoverMD, LyndeCW.Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.J Eur Acad Dermatol Venereol2006; 20: 1188–93, doi:10.1111/j.1468-3083.2006.01698.x.
116.
FarkasB, PaulC, DobozyA.Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and noninsulin-dependent diabetes mellitus: a multicentre trial.Br J Dermatol2002; 146: 254–60, doi:10.1046/j.1365-2133.2002.04606.x.
117.
Al-MutairiN, EassaBI, Al-RqobahDA.Clinical and mycologic characteristics of onychomycosis in diabetic patients.Acta Dermatovenerol Croat2010; 18: 84–91.
118.
AlbreskiDA, GrossEG.The safety of itraconazole in the diabetic population.J Am Podiatr Med Assoc1999; 89: 339–45, doi:10.7547/87507315-89-7-339.
119.
VerspeeltJ, MarynissenG, GuptaAK.Safety of itraconazole in diabetic patients.Dermatol Basel Switz1999; 198: 382–4, doi:10.1159/000018152.
120.
MatriccianiL, TalbotK, JonesS.Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.J Foot Ankle Res2011; 4: 26, doi:10.1186/1757-1146-4-26.
121.
RichP.Onychomycosis and tinea pedis in patients with diabetes.J Am Acad Dermatol2000; 43 (5 Suppl): S130–4, doi:10.1067/mjd.2000.110376.
122.
Moreno-CoutiñoG, ArenasR, Reyes-TeránG.Improvement in onychomycosis after initiation of combined antiretroviral therapy.Int J Dermatol2013; 52: 311–3, doi:10.1111/j.1365-4632.2011.05346.x
123.
TachikawaN, YasuokaA, OkaS.Improvement of onychomycosis without antifungal therapy after initiation of highly active antiretroviral therapy (HAART) in an HIV-infected patient.Jpn J Infect Dis1999; 52: 245–6.
124.
DompmartinD, DompmartinA, DeluolAM.Onychomycosis and AIDS. Clinical and laboratory findings in 62 patients.Int J Dermatol1990; 29: 337–9, doi:10.1111/j.1365-4362.1990.tb04755.x.
125.
Moreno-CoutinoG, ArenasR, Reyes-TeranG.Clinical presentation of onychomycosis in HIV/AIDS: a review of 280 Mexican cases.Indian J Dermatol2011; 56: 120–1, doi:10.4103/0019-5154.77577.
126.
SurjusheA, KamathR, OberaiC.A clinical and mycological study of onychomycosis in HIV infection.Indian J Dermatol Venereol Leprol2007; 73: 397–401, doi:10.4103/0378-6323.37057.
127.
KaviarasanPK, JaisankarTJ, ThappaDM.Clinical variations in dermatophytosis in HIV infected patients.Indian J Dermatol Venereol Leprol2002; 68: 213–6.
128.
GuptaAK, TabordaP, TabordaV.Epidemiology and prevalence of onychomycosis in HIV-positive individuals.Int J Dermatol2000; 39: 746–53, doi:10.1046/j.1365-4362.2000.00012.x.
129.
Sentamil SelviG, KamalamA, AjithadosK.Clinical and mycological features of dermatophytosis in renal transplant recipients.Mycoses1999; 42: 75–8, doi:10.1046/j.1439-0507.1999.00405.x.
HerranzP, GarcíaJ, De LucasR.Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine.Br J Dermatol1997; 137: 577–80, doi:10.1111/j.1365-2133.1997.tb03789.x.
132.
DanielCR3rd, NortonLA, ScherRK.The spectrum of nail disease in patients with human immunodeficiency virus infection.J Am Acad Dermatol1992; 27: 93–7, doi:10.1016/0190-9622(92)70163-A.
133.
MillikanLE.Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients.Cutis2001; 68: 6–14.
134.
NandwaniR, ParnellA, YouleM.Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis.Br J Dermatol1996; 134: 22–4, doi:10.1111/j.1365-2133.1996.tb15655.x.
135.
LoAC, LuiSL, LoWK.The interaction of terbinafine and cyclosporine A in renal transplant patients.Br J Clin Pharmacol1997; 43: 340–1.
136.
JensenP, LehneG, FauchaldP.Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection.Acta Derm Venereol1996; 76: 280–1.
137.
LeeKH, KimYS, KimMS.Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients.Transplant Proc1996; 28: 1488–9.
138.
ConantMA.The AIDS epidemic.J Am Acad Dermatol1994; 31 (3 Pt 2): S47–50, doi:10.1016/S0190-9622(08)81267-4.
HofmannH, BräutigamM, WeidingerG.Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group.Arch Dermatol1995; 131: 919–22, doi:10.1001/archderm.1995.01690200057011.
141.
EvansEG, SigurgeirssonB.Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.BMJ1999; 318: 1031–5, doi:10.1136/bmj.318.7190.1031.
142.
DegreefH, del PalacioA, MygindS.Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis.Acta Derm Venereol1999; 79: 221–3, doi:10.1080/000155599750011020.
143.
BaranR, FeuilhadeM, CombernaleP.A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.Br J Dermatol2000; 142: 1177–83, doi:10.1046/j.1365-2133.2000.03545.x.
144.
JenningsMB, PollakR, HarklessLB.Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement IRON-CLAD, a large, randomized, open-label, multicenter trial.J Am Podiatr Med Assoc2006; 96: 465–73, doi:10.7547/0960465.
145.
BaranR, SigurgeirssonB, de BerkerD.A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.Br J Dermatol2007; 157: 149–57, doi:10.1111/j.1365-2133.2007.07974.x.
146.
SigurgeirssonB, BillsteinS, RantanenT.L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis.Br J Dermatol1999; 141: 5–14, doi:10.1046/j.1365-2133.1999.00008.x.
147.
LechaM.Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain.Br J Dermatol2001; 145: 21–6, doi:10.1046/j.1365-2133.2001.145s60021.x.
148.
Montero-GeiF, Robles-SotoME, SchlagerH.Fluconazole in the treatment of severe onychomycosis.Int J Dermatol1996; 35: 587–8, doi:10.1111/j.1365-4362.1996.tb03666.x.
